argenx (ARGX) · empasiprubart
Wording changed · A neutral label for the two timing statements. It says nothing about the program’s results.
Before
Stated timing: fourth quarter of 2026
Topline results from registrational EMPASSION study (MMN) expected in fourth quarter of 2026
EX-99.1 · filed · SEC filing
After
Stated timing: in December 2026
Phase 3 MMN data for empasiprubart expected in December 2026
6-K · filed · SEC filing
Dots are filing dates. Bars show resolved calendar periods; timing wording stays as stated.
Sources: EX-99.1 filed Jul 23, 2026; 6-K filed Oct 22, 2026.
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/ARGX-empasiprubart-2026-10-22, data as of Oct 25, 2026
https://www.orionbiotechai.com/changes/ARGX-empasiprubart-2026-10-22
argenx (ARGX) pipeline and stated timing · Calendar · Companies A–Z · Follow by RSS